Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its late-stage product candidate, voxelotor (GBT440), for the treatment of sickle cell disease. Source
No articles found.
Ra PharmaÂŽ is a clinical-stage biopharmaceutical company using a proprietary pept...
Ra PharmaÂŽ is a clinical-stage biopharmaceutic...
Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on ...
Syndax Pharmaceuticals, Inc. is a late-stage bi...
We are a clinical-stage biopharmaceutical company committed to realizing the promi...
We are a clinical-stage biopharmaceutical compa...
Verona Pharma plc is a clinical stage biopharmaceutical company focused on the dev...
Verona Pharma plc is a clinical stage biopharma...
Neuralstem is a biopharmaceutical company developing novel treatments for nervous ...
Neuralstem is a biopharmaceutical company devel...
Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to ...
Rexahn Pharmaceuticals is a clinical stage biop...
Spectrum Pharmaceuticals is a leading biotechnology company with a focus in Oncolo...
Spectrum Pharmaceuticals is a leading biotechno...
Join the National Investor Network and get the latest information with your interests in mind.